-
Eight hiv-infected patients (mean CD4+ t cell count 622 cells/uL) who had been receiving effective HAART for an average of 8.4 years were included in this study. PBMCs were obtained by leukapheresis and endoscopic terminal ileum biopsies were performed to obtain samples of Gut-Associated Lymphoid Tissue (GALT).
-
In This Issue: FDA drug approval to change? Urinary incontinence in women; how metabolism of certain drugs can be predicted by genetic analysis; bowel preps may compromise renal function especially in the elderly according to a new study; FDA Actions.
-
Clinicians are becoming more attuned to the many complications of influenza, particularly with the high morbidity and mortality seen with H5N1 strains spreading around the world.
-
-
The adenomatous polyp (ADP) is recognized as the primary predecessor of colon cancer (CCA), prompting management strategies to identify and remove ADP.
-
Two recent studies suggest that rapid TIA evaluation and treatment can reduce stroke risk.
-
Bendamustine has received FDA approval, after priority review, for the treatment of chronic lymphocytic leukemia.
-
A statistically significant improvement in symptoms was observed in the treatment groups, with the honey-child group scoring the best, and the no treatment group doing the most poorly.
-
Mild TBI may be associated with brain microhemorrhages and white matter disruption, even with mild or absent symptoms of a postconcussion syndrome.
-
The proton pump inhibitor rabeprazole is said to provide rapid acid inhibition, but clinical implications of this have been uncertain. This study shows that a single dose of rabeprazole 20 mg administered 5 hours before therapeutic dosing of aspirin significantly decreases gastroduodenal damage.